Chiara Lestuzzi,Antonino De Paoli,Tanja Baresic et al.
Chiara Lestuzzi et al.
Primary malignant cardiac tumors are represented by sarcomas and non-Hodgkin lymphomas. They are rare, affect mostly patients in the fourth decade of life and have a severe prognosis. Both the diagnosis and the treatment require a multidisc...
Juan Caro Codón,Sandra O Rosillo Rodríguez,Teresa López Fernández
Juan Caro Codón
Screening programs and contemporary multidisciplinary management of oncologic patients have resulted in lower mortality and improved outcomes. Nevertheless, treatment-related cardiac toxicity has been recognized as a major side effect, nega...
Nieves Montoro,Jose Luis López-Sendón
Nieves Montoro
Progress in cancer treatment has significantly improved survival of patients with cancer. However, the incidence of cardiovascular diseases such as left ventricular dysfunction (LVD) and chronic heart failure (HF) is increasing due to the l...
Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training [0.03%]
有氧运动调节霍奇金淋巴瘤的心血管毒性：潜在作用及机制研究
Anthony F Yu,Lee W Jones
Anthony F Yu
Hodgkin lymphoma (HL) outcomes have improved due to advances in cancer treatment. However, HL survivors remain at increased risk for cardiovascular (CV) morbidity and mortality related to the long-term cardiotoxicity of HL treatment, partic...
Susan Piper,Theresa McDonagh
Susan Piper
Advances in chemotherapeutic agents over the past two decades have resulted in significantly improved cancer survival rates. Cardiac toxicity, however, has emerged as a leading cause of morbidity, both during and years after treatment. One ...
Neil Mangrolia,Vikrant Nayar,Peter J Pugh
Neil Mangrolia
A substantial proportion of patients who undergo cardiac rhythm device implantation receive anticoagulation to prevent thromboembolism. Many patients have coexisting cardiovascular diseases treated with antiplatelet therapy. Anticoagulation...
Luís Mont,Francisco Marín,Fernando García-Bragado Dalmau et al.
Luís Mont et al.
Rivaroxaban has proven efficacious in a variety of conditions. In fact, rivaroxaban has been approved for the prevention of venous thromboembolism after elective hip or knee replacement surgery, for the prevention and treatment of deep vein...
Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery [0.03%]
氨曲南对肺孢子菌肺炎患者免疫重建的影响
Carolina Chic Acevedo,Francisco Velasco,Concepción Herrera
Carolina Chic Acevedo
Rivaroxaban is a once-daily oral anticoagulant currently indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for the prevention and treatment of venous or pulmo...
Case Reports
Future cardiology. 2015 Sep;11(5):525-9. DOI:10.2217/fca.15.38 2015
Alternative stents in ST-segment elevation myocardial infarction: improving the efficacy of primary percutaneous coronary intervention [0.03%]
ST段抬高型心肌梗死的替代支架：提高直接经皮冠状动脉介入治疗的疗效
Tuncay Yetgin,Shimpei Nakatani,Yoshinobu Onuma et al.
Tuncay Yetgin et al.
Despite the efficacy of primary percutaneous coronary intervention in achieving epicardial reperfusion in ST-segment elevation myocardial infarction, it is often limited by impaired microvascular perfusion attributable to distal embolizatio...
An update on insertable cardiac monitors: examining the latest clinical evidence and technology for arrhythmia management [0.03%]
可植入心脏监测器的最新进展：评估心律失常管理的最新临床证据和技术
Flemming J Olsen,Tor Biering-Sørensen,Derk W Krieger
Flemming J Olsen
Continuous cardiac rhythm monitoring has undergone compelling progress over the past decades. Cardiac monitoring has emerged from 12-lead electrocardiograms being performed at the discretion of the treating physician to in-hospital telemetr...